Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Account Payables (2016 - 2025)

Kiora Pharmaceuticals' Change in Account Payables history spans 11 years, with the latest figure at $655913.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 391.69% year-over-year to $655913.0; the TTM value through Dec 2025 reached $1.1 million, up 397.49%, while the annual FY2025 figure was $1.1 million, 397.49% up from the prior year.
  • Change in Account Payables reached $655913.0 in Q4 2025 per KPRX's latest filing, up from -$40564.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.2 million in Q1 2025 to a low of -$662048.0 in Q2 2025.
  • Average Change in Account Payables over 5 years is $22000.4, with a median of $15012.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: soared 2461.65% in 2024, then tumbled 1030.78% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$300790.0 in 2021, then surged by 147.09% to $141641.0 in 2022, then tumbled by 71.31% to $40635.0 in 2023, then crashed by 653.37% to -$224863.0 in 2024, then soared by 391.69% to $655913.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Change in Account Payables are $655913.0 (Q4 2025), -$40564.0 (Q3 2025), and -$662048.0 (Q2 2025).